Abstract:Background Epidermal growth factor (EGF) is implicated in the pathogenesis of schizophrenia, suggesting possible value as a biomarker for disease severity or treatment response. However, basal EGF levels and changes during treatment are inconsistent across studies. The goal of this study is to compare serum EGF in schizophrenia patients before and after treatment with antipsychotics alone or combined with electroconvulsive therapy (ECT). Method Patients meeting DSM-IV diagnostic criteria for schizophrenia were recruited from June 2013 to December 2015 (n = 186) and followed up after 8 weeks of treatment with antipsychotics alone (n = 119, drug group) or combined with ECT (n = 67, ECT group). Serum EGF levels were measured by ELISA and compared among patients and 74 healthy control subjects. Psychopathology and clinical effects were assessed using the Positive and Negative Syndrome Scale (PANSS). Results Basal serum EGF was significantly lower in the entire patient cohort compared to healthy controls (P < 0.05). Repeated-measures ANOVA showed no main effect of time (F = 1.273; P = 0.261), time × group interaction (F = 1.228; P = 0.270), main effect of clinical response (F = 0.191; P = 0.663), or group × clinical interaction (F = 1.765; P = 0.186) on serum EGF. Serum EGF levels did not change significantly following antipsychotic drug or combined therapy (P > 0.05). Additionally, neither basal EGF nor EGF change was associated with the clinical response to drug or combined treatment (P > 0.05). However, baseline serum EGF was weakly associated with PANSS positive score (pretreatment: r = 0.206, posttreatment: r = 0.201) and general symptom score (pretreatment: r = −0.244). Serum EGF was also associated with duration of illness (pretreatment: r = 0.285, posttreatment: r = −0.231). Conclusions Serum EGF concentration is low in schizophrenia but is unchanged following treatment with antipsychotics alone or combined with ECT, regardless of clinical response. Thus, serum EGF is not a surrogate biomarker for treatment response and is unlikely to be involved in the therapeutic mechanisms of antipsychotics or ECT.

Altered serum levels of vascular endothelial growth factor in first-episode drug-naïve and chronic medicated schizophrenia.

Decreased Serum EGF in First-episode and Chronic Schizophrenia Patients: Negative Correlation with Psychopathology

The relationship between the alterations in metabolite levels in the dorsolateral prefrontal cortex and clinical symptoms of patients with first-episode schizophrenia: a one year follow-up study.

Level of Vascular Endothelial Growth Factor and Its Relationship with Symptoms in Stable Schizophrenia. J

Baseline serum vascular endothelial growth factor levels predict treatment response to antipsychotic medication in patients with schizophrenia.

Increased Serum FGF2 Levels in First-Episode, Drug-Free Patients with Schizophrenia.

Altered Serum Tumor Necrosis Factor and Interleukin-1β in First-Episode Drug-Naive and Chronic Schizophrenia

Neurocognition and social cognition in remitted first-episode schizophrenia: correlation with VEGF serum levels

Elevated serum vascular endothelial growth factor in treatment-resistant schizophrenia treated with electroconvulsive therapy: Positive association with therapeutic effects.

Cognitive Impairment in First-Episode Drug-Naïve Patients with Schizophrenia: Relationships with Serum Concentrations of Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor.

Association Between Depressive Symptoms and Serum Brain-Derived Neurotrophic Factor Levels in Patients With First-Episode and Drug-Naïve Schizophrenia

Decreased serum VEGF and NRG1β1 levels in male patients with chronic schizophrenia: VEGF correlation with clinical symptoms and cognitive deficits

Altered Peripheral Immune Profiles in First-Episode, Drug-Free Patients With Schizophrenia: Response to Antipsychotic Medications

Relationships Between Dorsolateral Prefrontal Cortex Metabolic Change and Cognitive Impairment in First-Episode Neuroleptic-Naive Schizophrenia Patients.

Serum Epidermal Growth Factor is Low in Schizophrenia and Not Affected by Antipsychotics Alone or Combined with Electroconvulsive Therapy

Vascular endothelial growth factor in major depressive disorder, schizophrenia, and bipolar disorder: A network meta-analysis

Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal Fmri Study

Peripheral Blood Levels of Brain-Derived Neurotrophic Factor in Patients with First Episode Psychosis: A Systematic Review and Meta-Analysis

Alterations in Spontaneous Brain Activity in Drug-Na?ve First-Episode Schizophrenia: An Anatomical/Activation Likelihood Estimation Meta-Analysis

Alterations in Spontaneous Brain Activity in Drug-Naïve First-Episode Schizophrenia: an Anatomical/Activation Likelihood Estimation Meta-Analysis

Serum Levels of Tumor Necrosis Factor-α and Vascular Endothelial Growth Factor in the Subtypes of Clinical High Risk Individuals: A Prospective Cohort Study [response to Letter].